Vergent Bioscience Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series C
  • (In Progress)

  • Latest Deal Amount
  • $20M

  • Investors
  • 7

Vergent Bioscience General Information

Description

Developer of molecular imaging technology designed to detect cancerous tissue during surgery. The company offers tumor-activated imaging agents that identify malignant tissue not visible under conventional lighting, enabling surgeons to locate tumors and guide tissue removal during minimally invasive and robotic cancer procedures.

Contact Information

Formerly Known As
In Vivo Technologies, Intracellular Technologies, In Vivo Tracer Technologies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5810 West 78th Street
  • Suite 222
  • Minneapolis, MN 55439
  • United States
+1 (952)
Primary Industry
Biotechnology
Corporate Office
  • 5810 West 78th Street
  • Suite 222
  • Minneapolis, MN 55439
  • United States
+1 (952)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vergent Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 07-Oct-2025 $20M In Progress Clinical Trials - Phase 3
4. Mezzanine 18-Feb-2025 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series B) 04-Oct-2022 Completed Clinical Trials - Phase 1
2. Grant 08-Sep-2022 $7.11M $11.9M Completed Clinical Trials - Phase 1
1. Later Stage VC (Series A) 23-Sep-2020 $11.9M $11.9M Completed Pre-Clinical Trials
To view Vergent Bioscience’s complete valuation and funding history, request access »

Vergent Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-2
Series C-1
Series B
Series A 28,530,868 $0.000100 $0.04 $0.44 $0.44 1x $0.44 22.78%
Founders 7,000,000 $0.000100 $0.03 $0.65 $0.65 1x $0.65 5.59%
To view Vergent Bioscience’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Vergent Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of molecular imaging technology designed to detect cancerous tissue during surgery. The company offers tumor-a
Biotechnology
Minneapolis, MN
10 As of 2023

Princeton, NJ
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vergent Bioscience Competitors (18)

One of Vergent Bioscience’s 18 competitors is Cytosorbents, a Corporation company based in Princeton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cytosorbents Corporation Princeton, NJ
Epic Sciences Venture Capital-Backed San Diego, CA
TScan Therapeutics Formerly VC-backed Waltham, MA
GeneCast Biotechnology Private Equity-Backed Wuxi, China
RareCyte Venture Capital-Backed Seattle, WA
You’re viewing 5 of 18 competitors. Get the full list »

Vergent Bioscience Patents

Vergent Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023215269-A1 Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment Active 02-Feb-2022
AU-2023215269-B2 Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment Active 02-Feb-2022
AU-2026223208-A1 Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment Pending 02-Feb-2022
EP-4472485-A1 Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment Pending 02-Feb-2022
EP-4472485-A4 Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment Pending 02-Feb-2022 A61B1/2676
To view Vergent Bioscience’s complete patent history, request access »

Vergent Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vergent Bioscience Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Intuitive Corporation Minority
Orlando Health Ventures Corporate Venture Capital Minority
UNC Health Ventures Corporate Venture Capital Minority
Windham Capital Partners Venture Capital Minority
National Institutes of Health Government
You’re viewing 5 of 7 investors. Get the full list »

Vergent Bioscience FAQs

  • When was Vergent Bioscience founded?

    Vergent Bioscience was founded in 2013.

  • Where is Vergent Bioscience headquartered?

    Vergent Bioscience is headquartered in Minneapolis, MN.

  • What is the size of Vergent Bioscience?

    Vergent Bioscience has 10 total employees.

  • What industry is Vergent Bioscience in?

    Vergent Bioscience’s primary industry is Biotechnology.

  • Is Vergent Bioscience a private or public company?

    Vergent Bioscience is a Private company.

  • What is the current valuation of Vergent Bioscience?

    The current valuation of Vergent Bioscience is .

  • What is Vergent Bioscience’s current revenue?

    The current revenue for Vergent Bioscience is .

  • How much funding has Vergent Bioscience raised over time?

    Vergent Bioscience has raised $37.8M.

  • Who are Vergent Bioscience’s investors?

    Intuitive, Orlando Health Ventures, UNC Health Ventures, Windham Capital Partners, and National Institutes of Health are 5 of 7 investors who have invested in Vergent Bioscience.

  • Who are Vergent Bioscience’s competitors?

    Cytosorbents, Epic Sciences, TScan Therapeutics, GeneCast Biotechnology, and RareCyte are some of the 18 competitors of Vergent Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process